[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA51815A - Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp - Google Patents

Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp

Info

Publication number
MA51815A
MA51815A MA051815A MA51815A MA51815A MA 51815 A MA51815 A MA 51815A MA 051815 A MA051815 A MA 051815A MA 51815 A MA51815 A MA 51815A MA 51815 A MA51815 A MA 51815A
Authority
MA
Morocco
Prior art keywords
migraines
prevention
treatment
methods
antibodies against
Prior art date
Application number
MA051815A
Other languages
English (en)
Inventor
Eduardo Dunayevich
Sun Hong
Robert A Lenz
Gabriel Vargas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA51815A publication Critical patent/MA51815A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
MA051815A 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp MA51815A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
MA51815A true MA51815A (fr) 2020-12-23

Family

ID=53969433

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41932A MA41932B1 (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines
MA051815A MA51815A (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41932A MA41932B1 (fr) 2015-04-24 2015-08-10 Méthodes de traitement ou de prévention de migraines

Country Status (30)

Country Link
US (3) US10259877B2 (fr)
EP (2) EP3285803B1 (fr)
JP (5) JP6392471B2 (fr)
KR (1) KR102464415B1 (fr)
CN (2) CN113908268A (fr)
AU (2) AU2015392215B2 (fr)
BR (1) BR112017022772A2 (fr)
CA (1) CA2984254C (fr)
CL (1) CL2017002686A1 (fr)
CY (1) CY1123211T1 (fr)
DK (1) DK3285803T3 (fr)
ES (1) ES2771925T3 (fr)
HK (1) HK1250914A1 (fr)
HR (1) HRP20200056T1 (fr)
HU (1) HUE048528T2 (fr)
IL (2) IL255114B (fr)
JO (2) JOP20200116A1 (fr)
LT (1) LT3285803T (fr)
MA (2) MA41932B1 (fr)
MX (2) MX2017013627A (fr)
PH (1) PH12017501934A1 (fr)
PL (1) PL3285803T3 (fr)
PT (1) PT3285803T (fr)
RS (1) RS59912B1 (fr)
RU (1) RU2707745C2 (fr)
SG (2) SG11201708607WA (fr)
SI (1) SI3285803T1 (fr)
TW (2) TWI799849B (fr)
WO (1) WO2016171742A1 (fr)
ZA (1) ZA201707179B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
EP3119431B1 (fr) 2014-03-21 2024-01-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes dirigés contre le peptide lié au gène de la calcitonine et leurs procédés d'utilisation
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
AU2018226811A1 (en) 2017-03-02 2019-09-26 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
US20200207844A1 (en) * 2017-09-12 2020-07-02 Igc Bio, Inc. Anti-vegf antibody
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
EP4302828A3 (fr) * 2018-07-05 2024-01-17 Allergan Pharmaceuticals International Limited Polythérapie avec des antagonistes du cgrp et des dérivés clostridiens
EP3908606A4 (fr) 2019-01-08 2022-11-23 H. Lundbeck A/S Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
JOP20210247A1 (ar) * 2019-05-02 2023-01-30 H Lundbeck As علاج الصداع باستخدام أجسام مضادة لـ cgrp
US20210130445A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
WO2021005497A1 (fr) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Antagonistes du cgrp et dérivés de clostridium pour le traitement de troubles associés à la dépression corticale envahissante
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
AU2020405091A1 (en) * 2019-12-18 2022-07-14 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
MX2023010115A (es) 2021-03-02 2023-11-09 Cgrp Diagnostics Gmbh Tratamiento y/o reducción de la aparición de la migraña.
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
WO1993001227A1 (fr) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
DK0640131T3 (da) 1992-03-17 1999-11-01 Novartis Ag Gensplejsere antistoffer
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
AU7953194A (en) 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ATE423553T1 (de) 2002-08-12 2009-03-15 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (fr) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CN1961000B (zh) 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
GEP20115333B (en) * 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
WO2007061692A2 (fr) 2005-11-18 2007-05-31 Merck & Co., Inc. Antagonistes du recepteur cgrp du spirolactam
WO2007076336A1 (fr) 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
WO2007133491A1 (fr) 2006-05-09 2007-11-22 Merck & Co., Inc. Antagonistes de récepteurs cgrp monocycliques substitués
WO2008112004A2 (fr) 2006-08-03 2008-09-18 Astrazeneca Ab ANTICORPS DIRIGÉS CONTRE αVβ6 ET LEURS UTILISATIONS
JP2010523663A (ja) 2007-04-11 2010-07-15 メルク・シャープ・エンド・ドーム・コーポレイション 第３級アミド、スルホンアミド、カルバミン酸及び尿素末端基をもつｃｇｒｐ受容体アンタゴニスト
US8143266B2 (en) 2007-04-16 2012-03-27 Merck, Sharp & Dohme Corp Aryl heterocyclic CGRP receptor antagonists
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
RU2467765C2 (ru) 2008-03-04 2012-11-27 Пфайзер Лимитед Способы лечения воспалительной боли
EP2299813B1 (fr) 2008-06-12 2015-12-16 Merck Sharp & Dohme Corp. Quinoléines 3- et 6-substituées ramifiées en tant qu antagonistes de récepteur cgrp
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
AU2009293471A1 (en) 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone CGRP receptor antagonists
AU2009298752A1 (en) 2008-10-03 2010-04-08 Merck Sharp & Dohme Corp. CGRP receptor antagonists
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
MX365813B (es) * 2011-05-20 2019-06-14 Alderbio Holdings Llc Uso de anticuerpos anti-cgrp o anti-cgrp o fragmentos de anticuerpo para tratar o prevenir formas crónicas y agudas de diarrea.
PL3495392T3 (pl) 2011-05-20 2021-12-13 H. Lundbeck A/S Kompozycje anty-cgrp i ich zastosowanie
CA3048709A1 (fr) * 2011-05-20 2012-11-29 Alderbio Holdings Llc Utilisation d'anticorps et de fragments d'anticorps anti-cgrp dans la prevention ou l'inhibition de la photophobie ou de l'aversion a la lumiere chez des sujets qui en ont besoin, en particulier des personnes souffrant de migraines
WO2014144632A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Anticorps anti-pac1 humains
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3119431B1 (fr) 2014-03-21 2024-01-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes dirigés contre le peptide lié au gène de la calcitonine et leurs procédés d'utilisation
CA2960756C (fr) * 2014-09-15 2023-08-01 Amgen Inc. Proteines de liaison antigeniques bispecifiques anti-recepteur cgrp/recepteur pac1 et leurs utilisations

Also Published As

Publication number Publication date
JO3559B1 (ar) 2020-07-05
JP2024138374A (ja) 2024-10-08
EP3653225B1 (fr) 2024-10-02
US20190256607A1 (en) 2019-08-22
RU2707745C2 (ru) 2019-11-29
RS59912B1 (sr) 2020-03-31
AU2015392215B2 (en) 2022-04-07
CY1123211T1 (el) 2021-12-31
JP6707590B2 (ja) 2020-06-10
EP3285803A1 (fr) 2018-02-28
TWI799849B (zh) 2023-04-21
CN113908268A (zh) 2022-01-11
SG10202004282RA (en) 2020-06-29
KR20180002711A (ko) 2018-01-08
JP7544766B2 (ja) 2024-09-03
JOP20200116A1 (ar) 2017-06-16
CL2017002686A1 (es) 2018-05-11
JP2018513871A (ja) 2018-05-31
HUE048528T2 (hu) 2020-07-28
MX2021013327A (es) 2021-11-17
IL255114B (en) 2022-04-01
US20160311913A1 (en) 2016-10-27
PL3285803T3 (pl) 2020-06-01
JP2020143115A (ja) 2020-09-10
ES2771925T3 (es) 2020-07-07
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
JP2022126724A (ja) 2022-08-30
WO2016171742A1 (fr) 2016-10-27
CN108156814B (zh) 2021-07-09
TWI728953B (zh) 2021-06-01
MX2017013627A (es) 2018-07-06
CA2984254A1 (fr) 2016-10-27
LT3285803T (lt) 2020-02-10
CN108156814A (zh) 2018-06-12
US11466090B2 (en) 2022-10-11
SI3285803T1 (sl) 2020-02-28
IL255114A0 (en) 2017-12-31
MA41932B1 (fr) 2020-04-30
RU2017140789A3 (fr) 2019-05-24
US20230020514A1 (en) 2023-01-19
SG11201708607WA (en) 2017-11-29
EP3285803B1 (fr) 2019-12-18
EP3653225A1 (fr) 2020-05-20
JP2019001800A (ja) 2019-01-10
TW201637667A (zh) 2016-11-01
PH12017501934A1 (en) 2018-03-19
AU2015392215A1 (en) 2017-11-09
HRP20200056T1 (hr) 2020-04-03
TW202130369A (zh) 2021-08-16
JP6392471B2 (ja) 2018-09-19
KR102464415B1 (ko) 2022-11-04
AU2022204866A1 (en) 2022-08-18
PT3285803T (pt) 2020-02-18
CA2984254C (fr) 2019-09-24
BR112017022772A2 (pt) 2018-07-31
DK3285803T3 (da) 2020-02-17
IL291153B2 (en) 2023-06-01
ZA201707179B (en) 2020-01-29
IL291153A (en) 2022-05-01
HK1250914A1 (zh) 2019-01-18

Similar Documents

Publication Publication Date Title
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
CL2018000732A1 (es) Variantes optimizadas de anticuerpos anti-vegf.
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55694A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA42366A (fr) Dispositif pour traiter, prévenir ou réduire la myopie, ou le risque de celle-ci
MA41449A (fr) Polythérapies pour le traitement de cancers
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
PH12016502167A1 (en) Hdl theraphy markers
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
BR112016027906A2 (pt) operação à prova de falhas de dispositivo montável no olho
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
MA42999A (fr) Polythérapie pour le traitement de malignités
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA45552A (fr) Compositions destinées au traitement de l'amylose
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
MA46734A (fr) Détection améliorée de changements de fluide
MA41202A (fr) Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
FR3022129B1 (fr) Baignoire de puericulture